Cell Biotech Co., Ltd.
Financials
Valuation Metrics
Cell Biotech Co., Ltd.'s Market Cap is ₩1416B. At end of 2025 it was ₩1232B. Ranked #1004 of 2,410 in KR market (top 42%), #498 of 1,631 on KOSDAQ (top 31%), #119 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 141.56B KRW | KR#1,004/2,410 Sec#119/231 |
| Revenue | 60.40B KRW | KR#1,693/2,410 Sec#113/231 |
| Net Income | 16.80B KRW | KR#773/2,410 Sec#53/231 |
| Total Assets | 136.57B KRW | KR#1,571/2,410 Sec#122/231 |
| Net Assets | 131.64B KRW | KR#1,218/2,410 Sec#91/231 |
| Employees | 123 | KR#1,482/2,410 Sec#118/231 |
| Value | ||
| P/E | 8.43x | KR#741/2,410 Sec#35/231 |
| P/B | 1.08x | KR#1,590/2,410 Sec#100/231 |
| PEG | 0.13x | KR#481/2,410 Sec#25/231 |
| P/S | 2.34x | KR#1,915/2,410 Sec#112/231 |
| EV/EBITDA | 12.32x | KR#771/2,410 Sec#41/231 |
| FCF Yield | 5.65% | KR#844/2,410 Sec#44/231 |
| Profitability | ||
| ROE | 12.76% | KR#426/2,410 Sec#29/231 |
| ROA | 12.30% | KR#179/2,410 Sec#15/231 |
| Op. Margin | 16.72% | KR#245/2,410 Sec#23/231 |
| Revenue Growth | 27.27% | KR#418/2,410 Sec#42/231 |
| Earnings Growth | 66.14% | KR#496/2,410 Sec#33/231 |
| Financial Health | ||
| Debt Ratio | 3.75% | KR#20/2,410 Sec#8/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 8.00B KRW | KR#773/2,410 Sec#44/231 |
| Cash | 17.14B KRW | KR#1,340/2,410 Sec#105/231 |
| Net Debt/EBITDA | -1.70x | KR#271/2,410 Sec#12/231 |
| Dividend | ||
| Div. Yield | 4.05% | KR#475/2,410 Sec#18/231 |
| Div. Growth | 33.33% | KR#328/2,410 Sec#17/231 |
| Performance | ||
| 1Y Return | 28.17% | KR#288/2,410 Sec#16/231 |
| 1M Return | -3.46% | KR#500/2,410 Sec#54/231 |
| From 52W High | -18.59% | KR#190/2,410 Sec#10/231 |
| 1Y MDD | -18.28% | KR#49/2,410 Sec#2/231 |
| Trading | ||
| Volume | 3,413 shares | KR#2,239/2,410 Sec#224/231 |
| Trading Value | 50.7M KRW | KR#1,912/2,410 Sec#201/231 |
| Foreign Own. | 4.22% | KR#997/2,410 Sec#90/231 |
| Per Share | ||
| EPS | 1,787 KRW | KR#485/2,410 Sec#30/231 |
| BPS | 14,004 KRW | KR#745/2,410 Sec#50/231 |
Company Info
Cell Biotech was established in 1995 for the research and manufacturing of probiotic lactic acid bacteria products and was listed on KOSDAQ in 2002. The company offers a one-stop solution from probiotic strain development to finished product manufacturing and distribution, achieving the top export position in 2023. By leveraging its dual-coating technology and launching personalized 'Cellbiom' products, Cell Biotech is expanding its business scope and product competitiveness. Cell Biotech is headquartered in Gimpo-si, Gyeonggi-do.